Patents by Inventor Srinivas Kaveri

Srinivas Kaveri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Demannosylated recombinant factor VIII for the treatment of patients with haemophilia A
    Patent number: 8802620
    Abstract: There is provided in accordance with the practice of this invention a demannosylated Factor VIII, the immunogenicity of which is substantially decreased or abolished in Human. The modified factor VIII is disclosed together with the modified amino acid sequence, changed by at least one substitution. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory anti-FVIII antibodies.
    Type: Grant
    Filed: April 21, 2008
    Date of Patent: August 12, 2014
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), LFB Biotechnologies
    Inventors: Abdessatar Sami Chtourou, Sébastien Lacroix-Desmazes, Srinivas Kaveri, Suryasarathi Dasgupta, Jagaadeesh Bayry
  • Method For Diagnosing Thrombophilia
    Publication number: 20120115171
    Abstract: The invention relates to a method for diagnosing thrombophilia in a subject suffering from HIV or from a systemic auto-immune disease, said method comprising determining in a blood sample obtained from said subject the level of free Protein S having Activated Protein C (APC) cofactor activity and the level of total Protein S.
    Type: Application
    Filed: May 7, 2010
    Publication date: May 10, 2012
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, UNIVERSITE RENE DESCARTES PARIS 5, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS
    Inventors: Sebastien Lacroix-des-Mazes, Vincent Mallet, Srinivas Kaveri, Stanislas Pol
  • DEMANNOSYLATED RECOMBINANT FACTOR VIII [[VII]] FOR THE TREATMENT OF PATIENTS WITH HAEMOPHILIA A
    Publication number: 20100197578
    Abstract: There is provided in accordance with the practice of this invention a demannosylated Factor VIII, the immunogenicity of which is substantially decreased or abolished in Human. The modified factor VIII is disclosed together with the modified amino acid sequence, changed by at least one substitution. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory anti-FVIII antibodies.
    Type: Application
    Filed: April 21, 2008
    Publication date: August 5, 2010
    Applicants: LFB Biotechnologies, Institut National De La Sante Et De La Recherche Medicale-Inserm
    Inventors: Abdessatar Sami Chtourou, Sébastien Lacroix-Desmazes, Srinivas Kaveri, Suryasarathi Dasgupta, Jagaadeesh Bayry
  • Catalytic anti-factor VIII allo-antibodies
    Publication number: 20090208512
    Abstract: The present invention relates to a method of determining the presence of catalytic anti-Factor VIII allo-antibodies capable of degrading Factor VIII in a mammal, and of characterising the cleavage sites in said Factor VIII molecule by said catalytic anti-Factor VIII allo-antibodies. It also relates to an anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor; and to a pharmaceutical composition comprising said catalytic anti-Factor VIII allo-antibodies which are capable of degrading Factor VIII and which originate from said method of determination; and further to a pharmaceutical composition comprising said anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor.
    Type: Application
    Filed: January 16, 2009
    Publication date: August 20, 2009
    Inventors: Srinivas Kaveri, Sebastien Lacroix-Desmazes, Michel Kazatchkine
  • Catalytic anti-factor VIII allo-antibodies
    Patent number: 7507540
    Abstract: A method is disclosed of determining the presence of catalytic anti-Factor VIII allo-antibodies capable of degrading Factor VIII in a mammal, and of characterising the cleavage sites in said Factor VIII molecule by said catalytic anti-Factor VIII allo-antibodies. It also relates to an anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor; and to a pharmaceutical composition comprising said catalytic anti-Factor VIII allo-antibodies which are capable of degrading Factor VIII and which originate from said method of determination; and further to a pharmaceutical composition comprising said anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor.
    Type: Grant
    Filed: July 18, 2000
    Date of Patent: March 24, 2009
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Bayer Pharma
    Inventors: Srinivas Kaveri, Sébastien Lacroix-Desmazes, Michel Kazatchkine